Organon & Co (OGN)
17.91
+0.04
(+0.22%)
USD |
NYSE |
Apr 18, 14:31
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 4.578B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -20.62% |
| Valuation | |
| PE Ratio | 4.477 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 0.7328 |
| Price to Book Value | -- |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.28 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -125.14 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
Profile
| Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women’s health, Biosimilars, and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio. |
| URL | https://www.organon.com |
| Investor Relations URL | N/A |
| HQ State/Province | New Jersey |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Small Cap/Value |
| Next Earnings Release | May. 03, 2024 (est.) |
| Last Earnings Release | Feb. 15, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Feb. 23, 2024 |
Ratings
Profile
| Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women’s health, Biosimilars, and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio. |
| URL | https://www.organon.com |
| Investor Relations URL | N/A |
| HQ State/Province | New Jersey |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Small Cap/Value |
| Next Earnings Release | May. 03, 2024 (est.) |
| Last Earnings Release | Feb. 15, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Feb. 23, 2024 |